We're in this Together:

Comprehensive solutions for developing COVID-19 assays, vaccines and novel therapeutics

To achieve success and meet urgent patient needs, drug developers need a partner who can provide a unique combination of services that extend their team's expertise and encompass drug development solutions and diagnostic capabilities.

Whether your team is identifying or repurposing a molecule, advancing to the clinic or recruiting patients, the Covance COVID-19 Response Teams are ready to connect you to the expertise you need and accelerate your path ahead, from diagnosis to development.

Achieve a new level of speed. Together, we can prevent populations from contracting COVID-19 and reduce mortality associated with the virus.

COVID-19 connections count.
Get direct medical, scientific, operational and regulatory support at any stage in your development. Across our global enterprise of drug development and diagnostics we offer our broad, established network that no other organization can match. Your result? You get the resources you need, when you need them, to inform your decisions – whether in early development or late-stage trials – and make your next move ahead.

- Drug Development & Diagnostic Capabilities
- Accelerated Study Start-Up & Assay Development
- Global Vaccine & Infectious Disease Experience
- Patient Engagement & Decentralized Trials
- Dedicated COVID-19 Response Teams
- Relationships with Regulatory Bodies

Reduce COVID-19 study startup times with on-demand support.
Turnaround time is key for these urgent studies. We've established dedicated study startup teams that can decrease preclinical start up times by 50%, decrease standard database creation timelines by up to 50%, along with dedicated medical writers to trim typical protocol development timelines by up to 66% for COVID-19 protocols. With Covance, you can get your study up and running, faster.

The power of the combined for patient recruitment.
Our collaboration across LabCorp and Covance provides you with several data-driven methods for efficient patient recruitment. We combine LabCorp de-identified COVID-19 testing data with Covance Central Laboratory clinical trial testing results to identify patient clusters that meet inclusion/exclusion criteria, pressure-test your protocol and help you anticipate the next COVID-19 "hot spots" that are near proven, experienced investigator sites. Every day counts, and we're here to tighten your recruitment timeline.

COVANCE LabCorp

Navigate a complex clinical trial setting with decentralized solutions.
Merge traditional drug development elements with decentralized trial tools and technologies to improve patient recruitment and expedite data collection in COVID-19 clinical studies. With decentralized solutions such as online enrollment, eConsent, app-based tools, home-based blood and swab collections, as well as LabCorp's U.S.-based Patient Service Centers (PSCs), we can reduce the need for on-site visits during COVID-19. Together, let's design a more patient-centric trial that delivers the data you need to succeed.

Extend your team's reach with our experience across the development lifecycle.

Global trials in vaccine and infectious diseases	Apply our knowledge gained in the last five years from: ▶ 700+ infectious disease trials ▶ 150+ vaccine trials ▶ 250+ vaccine and antiviral studies
Exploratory and non-GLP development	▶ In vitro pharmacology, exploratory biomarkers, assay development, validation and transfer ▶ In vivo safety assessment and pharmacology, animal models in key therapeutic areas
Bioanalytical Services & Safety Assessment (GLP)	▶ Safety assessment and metabolism ▶ Pharmacokinetic studies and PKPD modeling ▶ ADA (anti-drug antibody) assessment
Testing and Central Laboratory Services (CAP/CLIA, GCP, exploratory or BSL3 capabilities)	▶ Virology, genomics and biomarker assay development ▶ Molecular assays: RT-qPCR, sequencing, specialty assays ▶ Development of novel tests to support clinical trials: • Rapid point-of-care serological testing • ELISA for seropositivity testing • Immunoassays for inflammation (cytokine panels) ▶ Cell-based and micro assays: viral culture, neutralizing antibody assays
Biopharm CMC (GMP)	▶ Lot release testing in vitro and in vivo assays
Market Access & Phase IV	▶ Comprehensive post- and peri-approval studies ▶ Patient support services ▶ Patient safety and pharmacovigilance services

Together, we can match your regulatory requirements across the continuum.
The combined, comprehensive support that Covance and LabCorp can offer has never been more important. Spanning discovery to diagnosis to delivery, we're on a mission to increase your speed to market. We're all in this together – and we're fighting this pandemic to make a difference for patients. Patients can't wait. Neither can we.

Learn more about our COVID-19 testing, drug development and diagnostic solutions by visiting our COVID-19 site.

Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.

www.covance.com

 SSCVD021-0420

COVANCE LabCorp